国家: 台湾
语言: 中文
来源: 衛生福利部食品藥物管理署 (Ministry of Health and Welfare, Food And Drug Administration)
SALMETEROL XINAFOATE MICRONIZED;;FLUTICASONE PROPIONATE MICRONIZED
荷商葛蘭素史克藥廠股份有限公司台灣分公司 台北市中正區忠孝西路一段66號23-24樓 (86927438)
R03AK06
口腔吸入劑
SALMETEROL XINAFOATE MICRONIZED (1216002920) (equivalent to 25mcg of Salmeterol)MCG; FLUTICASONE PROPIONATE MICRONIZED (8406002220) MCG
金屬罐裝附吸入器
製 劑
須由醫師處方使用
GLAXO WELLCOME PRODUCTION 23 RUE LAVOISIER, ZONE INDUSTRIELLE NO.2, 27000 EVREUX, FRANCE FR
salmeterol and fluticasone
EVOFLO適用於可逆性呼吸道阻塞疾病(ROAD)之常規治療,包括適合使用支氣管擴張劑及皮質類固醇組合療法之患有氣喘的兒童與成人。這可能包括:正在使用長效乙型作用劑(β-AGONIST)及吸入型皮質類固醇之有效維持劑量的患者。正在接受吸入型皮質類固醇療法,而仍有症狀之患者。接受支氣管擴張劑之常規治療,而需要吸入型皮質類固醇之患者。EVOFLO適用於嚴重慢性阻塞性肺部疾病(FEV1 50%預期值,FEV1/FVC 70%)之維持治療,包括慢性支氣管炎和肺氣腫。
註銷日期: 2018/12/03; 註銷理由: 自請註銷; 有效日期: 2019/02/19; 英文品名: Evoflo 250 Evohaler
已註銷
2014-02-19
EVOFLO™ 125, 250 EVOHALER™ Salmeterol/fluticasone propionate QUALITATIVE AND QUANTITATIVE COMPOSITION Each single actuation of _EVOFLO_ provides: Salmeterol xinafoate equivalent to 25 micrograms of salmeterol and 125 or 250 micrograms of fluticasone propionate. PHARMACEUTICAL FORM Inhalation aerosol. CLINICAL PARTICULARS INDICATIONS ASTHMA - REVERSIBLE OBSTRUCTIVE AIRWAYS DISEASE (ROAD) _EVOFLO_ is indicated in the regular treatment of reversible obstructive airways disease (ROAD), including asthma in children and adults, where use of a combination (bronchodilator and inhaled corticosteroid) is appropriate. This may include: Patients on effective maintenance doses of long-acting beta-agonists and inhaled corticosteroids. Patients who are symptomatic on current inhaled corticosteroid therapy. Patients on regular bronchodilator therapy who require inhaled corticosteroids. CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) _EVOFLO_ is indicated for the maintenance treatment of severe chronic obstructive pulmonary disease (COPD) (FEV 1 <50% predicted normal, FEV 1 /FVC<70%) including chronic bronchitis and emphysema. DOSAGE AND ADMINISTRATION _EVOFLO_ Evohaler is for inhalation only. Patients should be made aware that _EVOFLO_ Evohaler must be used regularly for optimum benefit, even when asymptomatic. Patients should be regularly reassessed by a doctor, so that the strength of _EVOFLO_ they are receiving remains optimal and is only changed on medical advice. ASTHMA - REVERSIBLE OBSTRUCTIVE AIRWAYS DISEASE (ROAD) The dose should be titrated to the lowest dose at which effective control of symptoms is maintained. Where the control of symptoms is maintained with twice daily _EVOFLO_ , titration to the lowest effective dose could include _EVOFLO_ given once daily. Patients should be given the strength of _EVOFLO_ containing the appropriate fluticasone propionate dosage for the severity of their disease. Recommended Doses: Adults and adolescents 12 years and older:- Two inhalations of 25 micrograms salmeterol and 125 micro 阅读完整的文件